Clinical Trials Logo

Clinical Trial Summary

EBV positive tumor accounts for 8-9% of all gastric cancer (GC) patients. PD-1 antibody has been proved as third line therapy for PD-L1 positive gastric cancer. Previous studies showed that EBV(+) tumors exhibit high response to PD-1 antibody. In this phase II study, we will investigate the efficacy and safety of PD-1 antibody in EBV positive metastatic GC patients.


Clinical Trial Description

EBV positive metastatic GC patients who failed to standard chemotherapy will receive therapy of single agent, PD-1 antibody, SHR-1210, 200mg, every 2 weeks. The primary endpoint is response rate. Secondary endpoint is progress free survival, overall survival, safety and quality of life. Using the Simon two-stage sample size calculation, the sample size is 19. We will collect tissue and blood sample for exploratory analysis, including PD-L1 stuatus, tumor mutation burden, et al. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03755440
Study type Interventional
Source Sun Yat-sen University
Contact
Status Completed
Phase Phase 2
Start date December 1, 2018
Completion date December 31, 2020

See also
  Status Clinical Trial Phase
Not yet recruiting NCT02878278 - Differences Between Chidamide Taken Daily and Twice a Week in Therapeutic Effect,Pharmacokinetics, Pharmacodynamics and EB Virus Activation Phase 2
Terminated NCT01948180 - Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma Phase 2
Completed NCT01923766 - Cytotoxic T Cells to Prevent Virus Infections Phase 1
Terminated NCT03699904 - Epstein-Barr Virus Suppression in Chronic Obstructive Pulmonary Disease (EViSCO): a Phase 2 Randomised Control Trial Phase 2
Recruiting NCT01011712 - The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise
Active, not recruiting NCT04645147 - Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy Adults With or Without EBV Infection Phase 1
Terminated NCT02080416 - Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors Phase 0
Completed NCT02213068 - Belatacept 3 Month Post Transplant Conversion Study Phase 4
Recruiting NCT02779439 - Partially HLA-matched Third Party Antigen Specific T-cells for Infection Post-stem Cell or Solid Organ Transplantation Phase 1
Not yet recruiting NCT05677178 - Response Prediction in EBV-HLH Using Metabonomics Analysis
Completed NCT03650231 - Comparison of Technics for Determination of Epstein-Barr Virus Serological Diagnosis
Active, not recruiting NCT01945814 - Allogeneic Multivirus - Directed Cytotoxic T Lymphocytes (CTL) Phase 1
Recruiting NCT02007356 - A Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipients of Hematopoietic Stem Cell Transplantation With Post-transplant Viral Infections Using the Cytokine Capture System® Phase 2
Completed NCT03973723 - Plasma EBV DNA Monitoring in Post-treatment NPC Patients
Completed NCT02318030 - CNTRP POSITIVE Study